Note: this study is at multiple sites in North Carolina
| Study title | A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS (CC-93538-EE-001) |
| Disease or condition | Eosinophilic Esophagitis |
| Study type | Interventional (Clinical Trial) |
| Intervention/treatment | Cendakimab or placebo |
| Phase | 3 |
| Study site 1 | University of North Carolina at Chapel Hill |
| Study location | Chapel Hill |
| Principal investigator name and email | Evan Dellon, MD, MPH cedas@med.unc.edu |
| Study coordinator name and email | Tim Gee, timsgee@email.unc.edu |
| Phone contact | (919) 445-0747 |
| Study site 2 | Duke University |
| Study location | Durham |
| Principal investigator name and email | David Leiman, MD |
| Study coordinator name and email | Chris Efird, Chris.efird@duke.edu |
| Phone contact | (919) 668-5364 |
| Clinicaltrials.gov link | https://clinicaltrials.gov/ct2/show/NCT03678545 |